Table of Content



Chapter 1 Research Methodology and Scope
1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation And Validation
1.6 Model Details
1.6.1 Model 1: Commodity Flow Approach
1.6.2 Model 2: Volume Price Analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.1.1 Brazil Veterinary Vaccines Market Outlook, 2016 - 2027 (USD Million)
2.2 Segment Outlook
2.3 Brazil Veterinary Vaccines Market Summary, 2019
Chapter 3 Brazil Veterinary Vaccines Market Variables, Trends, and Scope
3.1 Penetration & Growth Prospect Mapping
3.2 Brazil Veterinary Vaccines Market dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rise in livestock population
3.2.1.2 Increasing prevalence of zoonotic diseases
3.2.1.3 Regulatory mandates for vaccination
3.2.2 MARKET RESTRAINT ANALYSIS
3.2.2.1 Volatility in exchange rates
3.2.2.2 Short product exclusivity period
3.3 Veterinary Vaccines Market Analysis Tools: Porters
3.3.1 Bargaining Power Of Suppliers: Low
3.3.2 Bargaining Power Of Buyers: Low
3.3.3 Threat Of Substitutes: Low
3.3.4 Threat Of New Entrants: Moderate
3.3.5 Competitive Rivalry: High
3.4 PESTEL Analysis
3.4.1 Political Landscape
3.4.2 Social & Economic Landscape
3.4.3 Technological Landscape
Chapter 4 Veterinary Vaccines Market: Competitive Analysis
4.1 Vendor Landscape
4.2 Market Leaders
4.2.1 Zoetis
4.2.2 Boehringer Ingelheim
4.2.3 Ceva Sante Animale
4.3 Market Innovators
4.4 Market Entry Strategies
4.5 Major Deals and Acquisitions
4.5.1 Mergers & Acquisitions
4.5.2 Product Launch
4.5.3 Expansion
4.6 Market Influencer Analysis
4.7 Consumer Preference Matrix
4.8 Estimated Company Market Share Analysis
Chapter 5 Brazil Veterinary Vaccines Market: Product Estimates and Forecasts to 2027
5.1 Brazil veterinary vaccines Market: Product Movement A nalysis
5.1.1 Attenuated Live Vaccines
5.1.1.1 Attenuated live vaccines market estimates and forecasts, 2016 - 2027 (USD Million)
5.1.2 DNA Vaccines
5.1.2.1 DNA vaccines market estimates and forecasts, 2016 - 2027 (USD Million)
5.1.3 Recombinant Vaccines
5.1.3.1 Recombinant vaccines market estimates and forecasts, 2016 - 2027 (USD Million)
5.1.4 Inactivated Vaccines
5.1.4.1 INACTIVATED vaccines market estimates and forecasts, 2016 - 2027 (USD Million)
5.1.5 Others Vaccines
5.1.5.1 Others vaccines market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 6 Brazil Veterinary Vaccines Market: Animal Type Estimates and Forecasts to 2027
6.1 Brazil Veterinary Vaccines Market: Animal Type Movement Analysis
6.1.1 Poultry
6.1.1.1 Poultry market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.2 Infectious bronchitis
6.1.1.2.1 Infectious bronchitis market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.3 Avian influenza
6.1.1.3.1 Avian influenza market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.4 Marek’s disease
6.1.1.4.1 Marek’s disease market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.5 Newcastle disease
6.1.1.5.1 Newcastle Disease market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.6 Salmonella
6.1.1.6.1 Salmonella market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.7 Avian Encephalomyelitis
6.1.1.7.1 Avian Encephalomyelitis market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.8 Fowl Cholera
6.1.1.8.1 Fowl Cholera market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.9 Egg Drop Syndrome 76 (EDS 76)
6.1.1.9.1 Egg Drop Syndrome 76 (EDS 76) market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.10 Infectious coryza
6.1.1.10.1 Infectious coryza market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.11 Combined Vaccines
6.1.1.11.1 Combined Vaccines market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.1.12 Others
6.1.1.12.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.2 AQUA
6.1.2.1 AQUA market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.2.2 Streptococcosis
6.1.2.2.1 Streptococcosis market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.2.3 Vibrio
6.1.2.3.1 Vibrio market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.2.4 Aeromonas
6.1.2.4.1 Aeromonas market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.2.5 Others
6.1.2.5.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3 Ruminants
6.1.3.1 Ruminants market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3.2 Foot & mouth disease (FMD)
6.1.3.2.1 Foot & Mouth Disease (FMD) market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3.3 Lumpy skin
6.1.3.3.1 Lumpy skin market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3.4 Rotavirus
6.1.3.4.1 Rotavirus market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3.5 Corona virus
6.1.3.5.1 Corona Virus market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3.6 E.coli
6.1.3.6.1 E.coli market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3.7 Blue tongue
6.1.3.7.1 Blue tongue market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3.8 Combined vaccines
6.1.3.8.1 Combined vaccines market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.3.9 Others
6.1.3.9.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.4 SWINE
6.1.4.1 Swine market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.4.2 Swine Influenza
6.1.4.2.1 Swine Influenza market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.4.3 Swine Fever
6.1.4.3.1 Swine Fever market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.4.4 Parvovirus
6.1.4.4.1 Parvovirus market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.4.5 PRRS
6.1.4.5.1 PRRS market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.4.6 Foot & Mouth Disease
6.1.4.6.1 Foot & Mouth Disease market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.4.7 Others
6.1.4.7.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5 Companion
6.1.5.1 Companion market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.2 Canine
6.1.5.2.1 Canine market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.2.2 Canine distemper
6.1.5.2.2.1 Canine distemper market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.2.3 Kennel cough
6.1.5.2.3.1 Kennel cough market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.2.4 Parvovirus
6.1.5.2.4.1 Parvovirus market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.2.5 Canine herpes
6.1.5.2.5.1 Canine herpes market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.2.6 Lyme disease
6.1.5.2.6.1 Lyme disease market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.3 Feline
6.1.5.3.1 Feline market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.3.2 Rhinotracheitis
6.1.5.3.2.1 Rhinotracheitis market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.3.3 Calicivirus
6.1.5.3.3.1 Calicivirus market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.3.4 Corona virus
6.1.5.3.4.1 Corona virus market estimates and forecasts, 2016 - 2027 (USD Million)
6.1.5.3.5 Panleukopenia
6.1.5.3.5.1 Panleukopenia market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 7 Company Profiles
7.1 Merck & Co., Inc.
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Zoetis
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Boehringer Ingelheim International GmbH
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Biog?nesis Bag? S.A.
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Ceva Sant? Animale
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Phibro Animal Health Corporation
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Ourofino Sa?de Animal
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Dechra Pharmaceuticals
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
7.9 Elanco
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Product Benchmarking
7.9.4 Strategic Initiatives



List of Tables



Table 1 List of secondary sources
Table 2 List Of distributors
Table 3 List of combined vaccines available in Brazil
Table 4 Leading market players anticipated to witness highest growth
Table 5 Brazil veterinary vaccines market, by Product type, 2016 - 2027 (USD Million)
Table 6 Brazil veterinary vaccines market, by animal type, 2016 - 2027 (USD Million)
Table 7 Brazil poultry vaccines market, by disease type, 2016 - 2027 (USD Million)
Table 8 Brazil ruminants vaccines market, by disease type, 2016 - 2027 (USD Million)
Table 9 Brazil swine vaccines market, by disease type, 2016 - 2027 (USD Million)
Table 10 Brazil companion vaccines market, by disease type, 2016 - 2027 (USD Million)
Table 11 Brazil aqua vaccines market, by disease type, 2016 - 2027 (USD Million)